Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | YES1 | P07947 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515484 | 0.85 | ALDH1A1 (0.48) | MAPKAPK2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL13632606 | 0.84 | JAK2 (0.63) | MAPKAPK2MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL7130500 | 0.76 | ABCG2 (0.63) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16514999 | 0.76 | MAPKAPK2 (0.49) | MAPKAPK2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL29575943 | 0.76 | MAPKAPK2 (0.49) | MAPKAPK2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL29847759 | 0.76 | MAPKAPK2 (0.47) | MAPKAPK2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL16514038 | 0.76 | MAPKAPK2 (0.47) | MAPKAPK2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL16513921 | 0.76 | MAPKAPK2 (0.47) | MAPKAPK2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL29847696 | 0.76 | MAPKAPK2 (0.47) | MAPKAPK2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL4892030 | 0.74 | EIF2AK2 (0.79) | MAPTMEN1KMT2ATDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | HRH4, NR1H2, NR1H3 | MAPKAPK2 4179/4885MAPT 3964/4885MEN1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.